Indian pharma CDMOs sector unfazed by proposed US tariffs: Report
Indian pharmaceutical CDMOs are anticipated to encounter minimal disruptions from the proposed US tariffs of 10-25 per cent. Despite the tariff concerns, industry experts believe the impact on costs will be marginal and offset by passing it onto customers, maintaining…
Read More